Similar to the results from BRAF+ melanoma patients, serum PLA1A levels were increased in MUT-NRAS melanoma patients compared to the level in the WT-NRAS (36.25 ± 16.24 μg/L vs 29.56 ± 14.26 μg/L), although this difference was not statistically significant (Fig. 4C; p > 0.05). This evidence concerns the gene PLA1A and melanoma.